Ramsay Health Care Ltd
F:RMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ramsay Health Care Ltd
F:RMY
|
AU |
|
S
|
Silgan Holdings Inc
F:SL3
|
US |
Ramsay Health Care Ltd
Ramsay Health Care runs private hospitals, day surgery centres, and some related healthcare facilities. It treats patients who need planned surgery, medical care, mental health services, rehabilitation, and other non-emergency hospital services. The company works closely with doctors and specialists who admit patients into its facilities. Its main customers are patients, private health insurers, public health systems in some markets, and doctors who use its hospitals. Ramsay makes money by charging for hospital stays, procedures, theatre time, and other clinical services, with payments often coming through insurers, governments, or the patients themselves. It also earns from operating hospital facilities under long-term partnerships and service arrangements. What makes Ramsay’s business different is that it sits in the middle of healthcare delivery: it does not make drugs or medical devices, but it provides the place where many of them are used. That gives it a role as a service provider and infrastructure owner in private healthcare, with revenue tied to patient admissions and the mix of procedures performed.
Ramsay Health Care runs private hospitals, day surgery centres, and some related healthcare facilities. It treats patients who need planned surgery, medical care, mental health services, rehabilitation, and other non-emergency hospital services. The company works closely with doctors and specialists who admit patients into its facilities.
Its main customers are patients, private health insurers, public health systems in some markets, and doctors who use its hospitals. Ramsay makes money by charging for hospital stays, procedures, theatre time, and other clinical services, with payments often coming through insurers, governments, or the patients themselves. It also earns from operating hospital facilities under long-term partnerships and service arrangements.
What makes Ramsay’s business different is that it sits in the middle of healthcare delivery: it does not make drugs or medical devices, but it provides the place where many of them are used. That gives it a role as a service provider and infrastructure owner in private healthcare, with revenue tied to patient admissions and the mix of procedures performed.
Strong Australia Performance: Ramsay Healthcare reported robust growth in its Australian hospital business, with revenue from customers up 8.2% and underlying EBIT up 7.3%, driven by higher acuity admissions, strong theater utilization, and improved PHI indexation.
Dividend Increase: The Board declared a fully franked dividend of $0.425 per share, up 6.3%, representing a 60% payout ratio of underlying earnings.
CapEx Guidance Lowered: Full-year CapEx has been revised down to $755–795 million, below previous guidance, reflecting greater capital discipline and a focus on higher-return projects.
Joondalup Mitigation On Track: Operational initiatives have partially offset funding headwinds at Joondalup, including successful efforts to reduce agency usage.
U.K. Headwinds & Strategy: NHS volume and funding pressures persist in the U.K., but Ramsay is focusing on private work, higher acuity cases, and operational efficiencies to offset slower NHS activity.
Elysium Turnaround Progressing: Elysium continues its turnaround with site closures and cost cuts, with further improvements expected under new leadership.
Ramsay Sante Demerger: The proposed in-specie distribution of Ramsay’s 52.8% stake in Ramsay Sante is moving forward, expected to complete by December 2026 and aimed at simplifying group structure.
Steady Outlook: Management expects continued EBIT growth in Australia and ongoing performance improvement initiatives across all regions.
